dammini), I. pacificus, I. ricinus (Europe), I. persulcatus (Asia))
Endemic to: The Americas and Eurasia
Symptoms: Fever, arthritis, neuroborreliosis, erythema migrans, cranial nerve palsy, carditis, fatigue, and influenza-like illness
Treatment: Antibiotics - amoxicillin in pregnant adults and children), (doxycycline in other adults
Relapsing fever (tick-borne relapsing fever, different from Lyme disease due to different Borrelia species and ticks)
Organisms: Borrelia species such as B. hermsii, B. parkeri, B. duttoni, B.  miyamotoi
Vector: Ornithodoros species
Regions : Primarily in Africa, Spain, Saudi Arabia, Asia in and certain areas of Canada and the western United States
Symptoms: Relapsing fever typically presents as recurring high fevers, flu-like symptoms, headaches, and muscular pain, with less common symptoms including rigors, joint pain, altered mentation, cough, sore throat, painful urination, and rash
Treatment: Antibiotics are the treatment for relapsing fever, with doxycycline, tetracycline, or erythromycin being the treatment of choice. Typhus Several diseases caused by Rickettsia bacteria (below)
Rocky Mountain spotted fever
Organism: Rickettsia rickettsii
Vector:  Wood tick (Dermacentor variabilis), D. andersoni
Region (US): East, Southwest
Vector: Amblyomma cajennense
Region (Brazil): São Paulo, Rio de Janeiro, Minas Gerais. Symptoms:Fever, headache, altered mental status, myalgia, and rash
Treatment: Antibiotic therapy, typically consisting of doxycycline or tetracycline
Helvetica spotted fever
Organism: Rickettsia helvetica
Region(R. helvetica): Confirmed common in ticks in Sweden, Switzerland, France, and Laos
Vector/region(s)#1: Ixodes ricinus is the main European vector. Symptoms: Most often small red spots, other symptoms are fever, muscle pain, headache and respiratory problems
Treatment: Broad-spectrum antibiotic therapy is needed, phenoxymethylpenicillin likely is sufficient.
Recombinant human factor VII, while initially looking promising in intracerebral hemorrhage, failed to show benefit following further study and is no longer recommended.In people with hemophilia type A and B who have a deficiency of factors VIII and IX, these two factors are administered for controlling bleeding or as prophylaxis medication before starting surgeries. However, in some cases they subsequently develop neutralizing antibodies, called inhibitors, against the drug. These inhibitors often increase over time and inhibit the action of coagulation in the  body. Recombinant factor VIIa, which is an activated form of factor VII, bypasses factors VIII and IX and causes coagulation without the need for factors VIII and IX. It cant be given without inhibitor. It is important for some patients to shift to proper blood factors according to their inhibitor titer. Other indications include use for patients with acquired hemophilia, people born with a deficiency of factor VII, and people with Glanzmanns thrombasthenia. Pharmacology
Mechanism of action
This treatment results in activation of the extrinsic pathway of blood coagulation. Coagulation factor VIIa (recombinant)-jncw
Coagulation factor VIIa (recombinant)-jncw (Sevenfact) is expressed in the mammary gland of genetically engineered rabbits and secreted into the rabbits milk. During purification and processing of the milk, FVII is converted into activated FVII (FVIIa).